CancerMaster Panel
Comprehensive panel for somatic cancer and immuno-oncology markers
Overview
Panels for Targeting Broad Range of Somatic Cancer Variants
The CancerMaster panel is designed to detect all variant types and immuno-oncology markers (MSI and TMB), which are crucial biomarkers for cancer immunotherapy. For CNV analysis, different cut-offs are applied according to the ratio of cancer cells. The panel is also designed to detect Epstein-Barr virus (EBV) and Human Papillomaviruses (HPV), allowing for the comprehensive analysis of cancer-associated genes.
Features & Benefits
Comprehensive Analysis of Cancer-associated Genes
CancerMaster is designed to have a broad range of targeting elements including somatic variants, IO-signatures (TMB, MSI), as well as other cancer associated biomarkers, such as EBV, and HPV, for all clinical diagnoses of different cancer types and applications for precision medicine
ANALYSIS OF EBV & HPV
ANALYSIS OF EBV & HPV
| EBV (Epstein-Barr Virus) | HPV (Human Papillomavirus) |
|---|---|
|
- Related disease - Lymphoma - Genes - EBV type1 (EBNA-2) |
- Related disease - Cervical cancer - Genes - HPV L1 gene (Analysis of a total of 24 types is possible) |
| Validation for detection of EBV type1 (EBNA - 2) in control specimens |
Analysis of the following 11 types of HPV types was completed using clinical specimens |
 |
 |
Extensive validation studies with actual clinical specimen
In order to achieve reproducible and robust panel performance, extensive validation tests have been conducted with various reference/standard samples as well as various clinical specimens.
Variants of CacerMaster (764 Samples)
Variants of CancerMaster (764 Samples)
Specification
| Gene count* | 524 genes |
|---|---|
| Covered region | Whole CDS, Custom regions of oncogenes, immune response genes, and EBV & HPV viruses |
| Target size | 2.5 Mb |
| Mutation type | SNV, Indel, CNV, Rearrangement, TMB, MSI, EBV, HPV |
| Sample type | FFPE, Fresh frozen tissue (> 50 ng of fragmented DNA) |
| Platform | All sequencers from Illumina, Thermo Fisher, MGI, PacBio, and Oxford Nanopore |
| Bioinformatics Support | ① Primary Analysis: FASTQ to annotated VCF ② Secondary Analysis: CNV, Large InDel, MSI, TMB ③ Tertiary Analysis: Clinical interpretation |
Specification - Gene List
CancerMaster Panel
- 524 genes | Gene count
- 2.5 Mb | Target Size
- Whole CDS, Custom regions of oncogenes, Immune response genes, and EBV & HPV viruses | Target Region
| ABL1 | ABL2 | ACVR1 | ACVR1B | ADAM29 | ADGRA2 | AKT1 | AKT2 | AKT3 | ALK | ALOX12B | ALOX15B | AMER1 | APC | APCDD1 | APEX1 | APOB | APOBEC1 | APOBEC3 A |
APOBEC3 B |
| AR | ARAF | ARFRP1 | ARID1A | ARID1B | ARID2 | ASXL1 | ATM | ATP11B | ATR | ATRX | AURKA | AURKB | AXIN1 | AXL | B2M | B3GAT1 | BACH1 | BAP1 | BARD1 |
| BCL2 | BCL2A1 | BCL2L1 | BCL2L2 | BCL6 | BCL9 | BCOR | BCORL1 | BCR | BIRC2 | BIRC3 | BLM | BRAF | BRCA1 | BRCA2 | BRD2 | BRD3 | BRD4 | BRIP1 | BTG1 |
| BTK | BTLA | CARD11 | CASP5 | CASP8 | CBFB | CBL | CCDC150 | CCDC168 | CCDC43 | CCL2 | CCL4 | CCND1 | CCND2 | CCND3 | CCNE1 | CD27 | CD274 | CD276 | CD28 |
| CD3D | CD3E | CD3G | CD4 | CD40 | CD44 | CD79A | CD79B | CD8A | CDC42 | CDC73 | CDH1 | CDH2 | CDH20 | CDH5 | CDK12 | CDK4 | CDK6 | CDK8 | CDKN1A |
| CDKN1B | CDKN2A | CDKN2B | CDKN2C | CDX2 | CEBPA | CHD1 | CHD2 | CHD4 | CHEK1 | CHEK2 | CHUK | CIC | CRBN | CREBBP | CRKL | CRLF2 | CSF1R | CSF2 | CSF2RA |
| CSF2RB | CSNK2A1 | CTCF | CTLA4 | CTNNA1 | CTNNB1 | CUL3 | CUL4A | CUL4B | CXCL10 | CXCL11 | CXCL9 | CXCR3 | CYLD | CYP17A1 | DAXX | DCUN1D1 | DDR2 | DICER1 | DIS3 |
| DNMT1 | DNMT3A | DOCK2 | DOT1L | EGFR | ELMO1 | EML4 | EMSY | EP300 | EPHA3 | EPHA5 | EPHA6 | EPHA7 | EPHB1 | EPHB4 | EPHB6 | ERBB2 | ERBB3 | ERBB4 | ERCC1 |
| ERCC2 | ERG | ERRFI1 | ESR1 | ETV1 | ETV4 | ETV5 | ETV6 | EWSR1 | EYA2 | EZH2 | FAM46C | FANCA | FANCC | FANCD2 | FANCE | FANCF | FANCG | FANCI | FANCL |
| FANCM | FAS | FAT1 | FAT3 | FBXW7 | FGF1 | FGF10 | FGF12 | FGF14 | FGF19 | FGF2 | FGF23 | FGF3 | FGF4 | FGF6 | FGF7 | FGFR1 | FGFR2 | FGFR3 | FGFR4 |
| FH | FLCN | FLT1 | FLT3 | FLT4 | FOXA1 | FOXL2 | FOXO3 | FOXP1 | FOXP3 | FRS2 | FUBP1 | GABRA6 | GAS6 | GATA1 | GATA2 | GATA3 | GATA4 | GATA6 | GID4 |
| GLI1 | GNA11 | GNA13 | GNAQ | GNAS | GRIN2A | GRM3 | GSK3B | GUCY1A2 | GZMA | GZMB | GZMH | H3F3A | HGF | HIST1H3B | HLA-A | HLA-B | HLA-C | HLA-DRA | HLA-E |
| HLA-F | HLA-G | HNF1A | HOXA3 | HRAS | HSD3B1 | HSP90AA1 | IDH1 | IDH2 | IDO1 | IDO2 | IFITM1 | IFITM3 | IFNA1 | IFNB1 | IFNG | IGF1 | IGF1R | IGF2 | IGF2R |
| IKBKE | IKZF1 | IL12A | IL12B | IL2 | IL23A | IL6 | IL7R | INHBA | INPP4B | INSR | IRF2 | IRF4 | IRS2 | ITGAE | ITK | JAK1 | JAK2 | JAK3 | JUN |
| KAT6A | KDM5A | KDM5C | KDM6A | KDR | KEAP1 | KEL | KIT | KLF4 | KLHL6 | KMT2A | KMT2B | KMT2C | KNSTRN | KRAS | LAG3 | LMO1 | LRP1B | LRP6 | LTK |
| LYN | LZTR1 | MAGI2 | MAGOH | MAML1 | MAP2K1 | MAP2K2 | MAP2K4 | MAP3K1 | MAP3K13 | MAPK1 | MAX | MCL1 | MDM2 | MDM4 | MED12 | MEF2B | MEN1 | MET | MITF |
| MLH1 | MPL | MRE11 | MSH2 | MSH6 | MTOR | MUTYH | MYB | MYC | MYCL | MYCN | MYD88 | MYO18A | NCOA3 | NCOR1 | NF1 | NF2 | NFE2L2 | NFKBIA | NKX2-1 |
| NKX2-8 | NKX3-1 | NOTCH1 | NOTCH2 | NOTCH3 | NOTCH4 | NPM1 | NRAS | NSD1 | NSD3 | NTRK1 | NTRK2 | NTRK3 | NUP93 | NUTM1 | PAK3 | PAK5 | PALB2 | PARK2 | PARP1 |
| PARP2 | PARP3 | PARP4 | PAX5 | PBRM1 | PDCD1 | PDCD1LG2 | PDGFRA | PDGFRB | PDK1 | PGR | PHF6 | PHLPP2 | PIK3C2B | PIK3C3 | PIK3CA | PIK3CB | PIK3CG | PIK3R1 | PIK3R2 |
| PKHD1 | PLCG1 | PLCG2 | PMS2 | PNP | PNRC1 | POLD1 | POLE | PPARG | PPP2R1A | PRDM1 | PREX2 | PRF1 | PRKAR1A | PRKCI | PRKDC | PRPF40B | PRSS8 | PTCH1 | PTCH2 |
| PTEN | PTK2 | PTPN11 | PTPRC | PTPRD | QKI | RAB35 | RAC1 | RAC2 | RAD17 | RAD50 | RAD51 | RAD51B | RAD51C | RAD51D | RAD52 | RAD54L | RAF1 | RANBP2 | RARA |
| RB1 | RBM10 | REL | RET | RHEB | RHOA | RHOB | RICTOR | RNF43 | ROBO1 | ROBO2 | ROS1 | RPA1 | RPS6KB1 | RPTOR | RUNX1 | RUNX1T1 | RUNX3 | SDHA | SDHB |
| SDHC | SDHD | SEMA3A | SEMA3E | SET | SETBP1 | SETD2 | SF3A1 | SF3B1 | SH2B3 | SKP2 | SLIT2 | SMAD2 | SMAD3 | SMAD4 | SMARCA1 | SMARCA4 | SMARCB1 | SMARCD1 | SMO |
| SNCAIP | SOCS1 | SOX10 | SOX2 | SOX9 | SPEN | SPOP | SPTA1 | SRC | SRSF1 | SRSF2 | SRSF7 | STAG2 | STAT3 | STAT4 | STK11 | SUFU | SYK | TACC3 | TAF1 |
| TBX22 | TBX3 | TERC | TERT | TET2 | TGFBR2 | TIAF1 | TIGIT | TIPARP | TMPRSS2 | TNF | TNFAIP3 | TNFRSF14 | TNFRSF18 | TNFRSF4 | TNFSF13B | TNKS | TNKS2 | TOP1 | TOP2A |
| TP53 | TRAF7 | TRRAP | TSC1 | TSC2 | TSHR | U2AF1 | U2AF2 | USP9X | VEGFA | VHL | VSIR | VTCN1 | WISP3 | WNT1 | WT1 | WWP1 | XBP1 | XPO1 | XRCC3 |
| ZBTB2 | ZNF217 | ZNF703 | ZRSR2 |
Related Products
CancerMaster
Designed to detect all types of variants and immuno-oncology markers including gene rearrangement in various somatic cancer-related and cancer-associated genes
OncoRisk
Comprehensive and specialized hereditary cancer panel for analyzing 31 oncogenes associated with inherited cancer
CancerScreen CDx
Covers all major genes, including coding exons, concerning mutation for FDA approved therapies
CAS
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Designed to detect all types of variants and immuno-oncology markers including gene rearrangement in various somatic cancer-related and cancer-associated genes
Comprehensive and specialized hereditary cancer panel for analyzing 31 oncogenes associated with inherited cancer
Covers all major genes, including coding exons, concerning mutation for FDA approved therapies
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Resources
Technical Resources
Safety Data Sheets
If you require the latest MSDS file, please contact us via ‘Contact Us‘.
MSDS_CancerMaster Panel_Illumina
MSDS_CancerMaster Panel_Thermo Fisher
MSDS_CancerMaster Panel_MGI
References
Cancer Research and Treatment
Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)
Koo DH, Jung M, Kim YH, Jeung HC, Zang DY, Bae WK, Kim H, Kim HS, Lee CK, Kwon WS, Chung HC. Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: a Multicenter Phase Ib/II Study (K-MASTER-13). Cancer Research and Treatment. 2024 Apr 29.
10.4143/crt.2023.1324
Experimental & Molecular Medicine
Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity
Yoon JG, Jang DG, Cho SG, Lee C, Noh SH, Seo SK, Yu JW, Chung HW, Han K, Kwon SS, Han DH. Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity. Experimental & Molecular Medicine. 2024 Mar;56(3):570-82.
10.1038/s12276-024-01172-8
Cancers
Discovery and Validation of Survival-Specific Genes in Papillary Renal Cell Carcinoma Using a Customized Next-Generation Sequencing Gene Panel
Hwang J, Bang S, Choi MH, Hong SH, Kim SW, Lee HE, Yang JH, Park US, Choi YJ. Discovery and Validation of Survival-Specific Genes in Papillary Renal Cell Carcinoma Using a Customized Next-Generation Sequencing Gene Panel. Cancers. 2024 Jan;16(11):2006.
10.3390/cancers16112006
Frontiers in Neurology
Case report: Compound heterozygous variants detected by next-generation sequencing in a Tunisian child with ataxia-telangiectasia
Ammous-Boukhris N, Abdelmaksoud-Dammak R, Ben Ayed-Guerfali D, Guidara S, Jallouli O, Kamoun H, Charfi Triki C, Mokdad-Gargouri R. Case report: Compound heterozygous variants detected by next-generation sequencing in a Tunisian child with ataxia-telangiectasia. Frontiers in Neurology. 2024 May 31;15:1344018.
10.3389/fneur.2024.1344018